Exploiting the PI3K/AKT pathway for cancer drug discovery

Bryan T. Hennessy; Debra L. Smith; Prahlad T. Ram; Yiling Lu; Gordon B. Mills

doi:10.1038/nrd1902

Exploiting the PI3K/AKT pathway for cancer drug discovery

Bryan T. Hennessy, Debra L. Smith, Prahlad T. Ram, Yiling Lu, Gordon B. Mills

Systems Biology

Research output: Contribution to journal › Review article › peer-review

1863 Scopus citations

Abstract

Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.

Original language	English (US)
Pages (from-to)	988-1004
Number of pages	17
Journal	Nature Reviews Drug Discovery
Volume	4
Issue number	12
DOIs	https://doi.org/10.1038/nrd1902
State	Published - Dec 2005

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1038/nrd1902

Cite this

@article{1a4aa8388bfe4ec286da22be43638f92,

title = "Exploiting the PI3K/AKT pathway for cancer drug discovery",

abstract = "Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.",

author = "Hennessy, {Bryan T.} and Smith, {Debra L.} and Ram, {Prahlad T.} and Yiling Lu and Mills, {Gordon B.}",

note = "Funding Information: The authors{\textquoteright} research is supported by National Institutes of Health (NIH) grants to G.B.M. as well as by a Department Of Defence grant to P.T.R., and Aventis Pharmaceutical M.D. Anderson fellowship award to B.T.H., and a training fellowship from the Keck Centern Pharmacoinformatic Training Program at the Gulf Coast Consortia (NIH grant) to D.L.S.",

year = "2005",

month = dec,

doi = "10.1038/nrd1902",

language = "English (US)",

volume = "4",

pages = "988--1004",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Exploiting the PI3K/AKT pathway for cancer drug discovery

AU - Hennessy, Bryan T.

AU - Smith, Debra L.

AU - Ram, Prahlad T.

AU - Lu, Yiling

AU - Mills, Gordon B.

N1 - Funding Information: The authors’ research is supported by National Institutes of Health (NIH) grants to G.B.M. as well as by a Department Of Defence grant to P.T.R., and Aventis Pharmaceutical M.D. Anderson fellowship award to B.T.H., and a training fellowship from the Keck Centern Pharmacoinformatic Training Program at the Gulf Coast Consortia (NIH grant) to D.L.S.

PY - 2005/12

Y1 - 2005/12

N2 - Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.

AB - Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.

UR - http://www.scopus.com/inward/record.url?scp=32044466838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044466838&partnerID=8YFLogxK

U2 - 10.1038/nrd1902

DO - 10.1038/nrd1902

M3 - Review article

C2 - 16341064

AN - SCOPUS:32044466838

SN - 1474-1776

VL - 4

SP - 988

EP - 1004

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 12

ER -

Exploiting the PI3K/AKT pathway for cancer drug discovery

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this